<DOC>
	<DOC>NCT02321397</DOC>
	<brief_summary>This study is aimed to demonstrate equivalence between combinations of lower strength OXN PR tablets (OXN PR LST) and single higher strength OXN PR tablets (OXN PR HST) taken at the same overall daily dose.</brief_summary>
	<brief_title>To Demonstrate Equivalence in Analgesic Efficacy &amp; Bowel Function Between OXN PR Higher Dose &amp; Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain</brief_title>
	<detailed_description>Study OXN3508 is a multicenter double-blind, double-dummy, randomised, cross-over, 2-period, phase III study in male and female subjects with severe non-malignant or malignant pain that requires around-the-clock opioid therapy at a daily dose of 120/60 mg or 160/80 mg oxycodone/naloxone prolonged release (OXN PR).</detailed_description>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Inclusion Criteria Subjects who are receiving WHO step III opioid analgesic medication for the treatment of nonmalignant or malignant pain. Documented history of nonmalignant or malignant pain that requires aroundtheclock opioid therapy Exclusion Criteria Females who are pregnant or lactating. Subjects with evidence or significant structural abnormalities of the gastrointestinal tract. Subjects with evidence of impaired liver/kidney function upon entry into the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>oxycodone naloxone combination</keyword>
	<keyword>severe chronic and non-malignant pain</keyword>
	<keyword>Malignant and non-malignant pain that requires around-the clock opioid therapy</keyword>
</DOC>